Processa Pharmaceuticals, Inc. — Director's Dealing 2024

Jul 18, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2024-07-16

Reporting Person: SKIBSTED RUSSELL (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-07-16	Restricted Stock Units	$0	A	28000	Acquired		Common Stock (28000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting of 50% on 7/16/25 and the remainder upon achievement of certain criteria.